These spatially resolved insights highlighted CDKN2A as a promising biomarker for predicting CRC resistance to chemotherapy (5‐fluorouracil) and radiotherapy, with significant implications for therapy‐resistant tumour niches. Here, CDKN2A is linked to colorectal carcinoma.